Skip to content

Net Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$92.53M+37.0%
Biogen logo
BiogenBIIB
$319.5M+32.8%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.64M-80.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$185M-22.5%
uniQure logo
uniQureQURE
-$53.54M-22.7%
Precigen logo
PrecigenPGEN
-$7.93M+85.4%

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s net income?
Taysha Gene Therapies, Inc. (TSHA) reported net income of -$42.41M in Q1 2026.
How has Taysha Gene Therapies, Inc.'s net income changed year-over-year?
Taysha Gene Therapies, Inc.'s net income decreased by 97.0% year-over-year, from -$21.53M to -$42.41M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s net income?
Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s net income has grown at a -14.5% compound annual growth rate (CAGR), from -$174.52M to -$109M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.